Table 2. Treatment Characteristics.
| Treatment characteristics | No. | No. (%) |
|---|---|---|
| NAC Regimen | 234 | |
| AC-T | 197 (84) | |
| AC-T + Carbo | 15 (6.4) | |
| TC | 8 (3.4) | |
| Other | 14 (6) | |
| Neoadjuvant anti-ERBB2 therapy | 144 | |
| HP | 144 (100) | |
| Adjuvant RT | 234 | |
| Yes | 205 (88) | |
| No | 29 (12) | |
| Nodal RTa | 234 | |
| Yes | 164 (70) | |
| No | 70 (30) | |
| Adjuvant endocrine therapy | 127 | |
| Yes | 109 (86) | |
| No | 18 (14) | |
| Endocrine therapy regimen | 107 | |
| Tamoxifenb | 42 (39) | |
| Aromatase inhibitorb | 66 (61) | |
| Toremifene | 1 (<1) | |
| Adjuvant anti-ERBB2 therapy | 144 | |
| Yes | 132 (92) | |
| No | 12 (8) |
Abbreviations: AC-T, adriamycin and cyclophosphamide followed by taxol; Carbo, carboplatin; ERBB2, Erb-B2 receptor tyrosine kinase 2 (formerly HER2, human epidermal growth factor receptor 2); HP, trastuzumab (H) and pertuzumab (P); NAC, neoadjuvant chemotherapy; RT, radiotherapy; TC, taxotere and cyclophosphamide.
a
Includes the ipsilateral level I and II axillary nodes, supraclavicular and infraclavicular fossa, and the internal mammary nodal chain in the first 3 intercostal spaces.
b
Ovarian suppression plus tamoxifen (n = 5); ovarian suppression plus aromatase inhibitor (n = 28).